How can Johnson & Johnson Innovation (JJI) help you reach your goals? We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a diverse team of science and transaction experts whose goal is to find high potential early-stage innovation and, if on strategy and a fit for Johnson & Johnson, create customized deal structures to help accelerate the science to the patient.
Every marketer wants the perfect story to tell. But if you’re in medicine, you don’t want it to be about yourself.
Earlier this year, vascular surgeon John Martin was testing a pocket-sized ultrasound device developed by Butterfly Network, a startup based in Guilford, Connecticut, that he’d just joined as chief medical officer.
1ST Biotherapeutics, Inc. (1ST Bio), a private Korean biotech company, and Neuraly Inc., a startup from Johns Hopkins School of Medicine, today announced a collaboration to co-develop novel brain penetrant c-Abl inhibitors for Parkinson’s disease. Recent research has shown that inhibitors to c-Abl could slow the progression of Parkinson’s disease. Parkinson’s disease, a chronic and progressive movement disorder, is the second most common neurodegenerative disease, affecting nearly one million people in the United States.
A plan to build 12M SF of mixed-use development on a 300-acre site near the Food and Drug Administration’s HQ in Montgomery County has been in the works for nearly a decade, and the developer feels confident it can break ground in a matter of months.
Six companies presenting innovative medical device solutions that address significant unmet needs in pediatric health were awarded a total of US$250,000 in grant money in San Jose, Calif. at the Fifth Annual Pediatric Device Innovation Symposium, organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System.
United Therapeutics Corp (NASDAQ: UTHR), which has an office in the Research Triangle, has received approval of a new inhalation device from the U.S. Food and Drug Administration (FDA) for use with its drug Tyvaso. Tyvaso, has been the focal point of a number of patent disputes. A treatment for pulmonary hypertension (PAH), the drug generates significant sales for the company.
Diabetes has long been one of the most expensive medical conditions. In 2013 spending on care for people with the disease in the United States topped $100 billion. But it is also one of the most amenable to simple, low-cost behavioral interventions. At Geisinger, we set out to improve the health of diabetic adults by providing them with free, nutritious food and a comprehensive suite of medical, dietetic, social, and environmental services.
Thursday, November 30, 2017 from 6:15 p.m. to 8:30 p.m. at Inova Center for Personalized Health 3225 Gallows Road, Fairfax VA
The Inova Personalized Health Accelerator has made it our mission to increase the speed at which innovation enters the health system.
To celebrate this new venture we’re kicking off with a launch event to inspire, align, and connect our talented professionals, dedicated investor base and up-and-coming innovative startups in the area.
Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NASDAQ:MGNX) announced today that the companies have entered into an exclusive global collaboration and license agreement for MacroGenics’ MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination with MGA012.
After seeing the strength of the six finalist projects and evaluating each of the teams’ proposals, TEDCO board members decided to up their $300,000 offer, and fund every one of them.
